Wednesday, 20 Nov 2019

You are here

Low Dose IL-2 Effective in Lupus

A double-blind, placebo-controlled clinical trial of low-dose IL-2 in patients with systemic lupus erythematosus (SLE) has shown  that low-dose IL-2 was clinically effective while expandng regulatory T cells and NK cells, which may benefit immune homeostasis in SLE patients.

SLE patients have been shown to be deficient in IL-2 and it is postulated that IL-2 therapy may induce and expand regulatory T cells to better control self-tolerance and autoimmunity. Prior pilot studies of low dose IL-2 in SLE have been encouraging.

While IL-2 immunotherapy has been tried in other conditoins (e.g., melanoma, etc.), use has often been limited by toxicities.

This clinical trial enrolled 60 patients with active SLE, who received either IL-2 (n=30) or placebo (n=30) for 12 weeks, and were followed for an additional 12 weeks. IL-2 at a dose of 1 million IU or placebo was administered subcutaneously every other day for 2 weeks and followed by a 2-week break as one treatment cycle. The primary endpoint was the SLE Responder Index-4 (SRI-4) at week 12.

At week 12, the low dose IL-2 group had greater SRI-4 responses (55.2%) than placebo (30%) (p=0.052). This superiority was maintained for the next 12 weeks off IL-2 (at week 24) with an SRI-4 response of 65.5% vs 36.7%, respectively (p=0.027).

Complete remission in lupus nephritis patients was seen in 54% on IL-2 vs 17% on placebo (p=0.036). Adverse events were not significantly different between groups, other than a few more injection site reactions (9 vs. 2), fever (4 vs. 0) and flu-like symptoms (3 vs. 0).

Patients treated with low-dose IL-2 had greater expansion of regulatory T cells, no change in CD4+ and CD8+ T cells and a significant increase natural killer cells after IL-2 therapy.

This is the first randomised, double-blind, placebo-controlled study of low-dose IL-2 in SLE, demonstrating efficacy and safety with expansion of regulatory T cells and NK cells, which may contribute to the restoration of immune homeostasis in SLE patients.

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Part 1:  The “P” in Prednisone stands for Poison...and Other Pearls

Everyone has life hacks.  Years of experience and doing the same things repetitively allow us to figure out little tricks to make life easier. A rat in a maze, finding itself at a dead end, will back up and search for a clearing. If this rat encounters its neighbor, it will transmit that information so the second rat won’t make the same mistake.

Protective Effects of ASA and Vasodilators in Systemic Sclerosis

A large cohort study suggests that the use of vasodilators and aspirin (ASA) in systemic sclerosis (SSc) may yield favorable  cardiovascular outcomes.

Myositis Patients at High Risk of Opportunistic Infections

Among patients with systemic rheumatic diseases, the highest incidence of opportunistic infections was seen in those with polymyositis/dermatomyositis (PM/DM), Taiwanese researchers found.

Warfarin Superior to Xarelto in Antiphospholipid Syndrome

A 3 year, multicenter, European, study shows that rivaroxaban was inferior to warfarin in preventing thrombosis in patients with antiphospholipid syndrome (APS) according to the Annals of Internal Medicine. Thus despite the inconvenience of warfarin, it remains the best option for patients with APS.

Declining Trends in Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis Mortality in the USA

Annals of Internal Medicine reports that age-adjusted mortality rates for antineutrophil cytoplasmic autoantibody–associated vasculitides (AAV) have improved over time - with a decline of nearly 2 percent per year in the United States from 1999 to 2017. Nevertheless, long-term outcomes continue to lag behind mortality rates of the general population.